DR56 DataRelease

Release Date: June 2025
New Studies: 20
Updated Studies: 10

New Studies

SDY2312: Molecular signatures in a Hepatitis B Vaccine-immunized neonatal Tissue Construct in vitro correlate with antibody response in vivo
Status:	New
Description:	Only three licensed vaccines are currently approved for neonatal use worldwide with recommended administration around the time of birth: Hepatitis B Vaccine (HBV), Oral Poliovirus Vaccine (OPV) and the Bacille Calmette-Guérin (BCG) tuberculosis vaccine. We have previously shown that baseline (pre-vaccination) and early vaccine-induced systemic changes in global molecular patterns- i.e., “OMIC” signatures -in the days immediately post-immunization can predict subsequent protective humoral and cellular immune responses. However, it is unclear how the exact timing and sequence of neonatal vaccination can affect signatures of immunogenicity and vaccine-induced protection in humans. Herein, we employ our 3-dimensional tissue construct model that was previously used to investigate and replicate human age- specific vaccine responses in vivo, to a) gain insights into vaccine-induced OMIC signatures after single vs combined vaccination and b) investigate the association between human in vitro OMIC signatures and human in vivo hepatitis B antibody titers, a universally-accepted correlate of vaccine-induced protection, from the same study participants.
Program/Contract:	Program Contract Human Immunology Project Consortium (HIPC) RFA-AI-15-041 Systems Biology To Identify Biomarkers Of Neonatal Vaccine Immunogenicity (Boston Children's)
DOI:	10.21430/m34t975slb
Subjects:	38
Study PI, contact:	Name Organization Site Ofer Levy Boston Children's Hospital Boston Children's Hospital, Harvard Medical School Tobias Kollmann University of British Columbia BC Children's Hospital, University of British Columbia Beate Kampmann Charité Centre for Global Health Charité Centre for Global Health Al Ozonoff Broad Institute of Harvard and MIT Boston Children's Hospital, Broad Institute of Harvard and MIT Scott Tebbutt University of British Columbia PROOF Centre, University of British Columbia Robert Hancock University of British Columbia PROOF Centre, University of British Columbia Hanno Steen Boston Children's Hospital Boston Children's Hospital Joann Diray-Arce Boston Children's Hospital Boston Children's Hospital, Harvard Medical School Guzman Sanchez-Schmitz Boston Children's Hospital Boston Children's Hospital Kinga Smolen Boston Children's Hospital Boston Children's Hospital Paolo Palma Bambino Gesù Childrens' Hospital Bambino Gesù Childrens' Hospital Amy Lee University of British Columbia University of British Columbia Ryan Brinkman University of British Columbia University of British Columbia Asimenia Angelidou Boston Children's Hospital Boston Children's Hospital Oludare Odumade Boston Children's Hospital Boston Children's Hospital, Harvard Medical School Simon van Haren Boston Children's Hospital Boston Children's Hospital Olubukola Idoko The Gambia at the London School of Hygiene and Tropical Medicine The Gambia at the London School of Hygiene and Tropical Medicine Annmarie Hoch Boston Children's Hospital Boston Children's Hospital Jing Chen Boston Children's Hospital Boston Children's Hospital Abhinav Checkervarty University of British Columbia University of British Columbia Caitlin Syphurs Boston Children's Hospital Boston Children's Hospital Arnaud Marchant Université libre de Bruxelles Université libre de Bruxelles Alansana Darboe The Gambia at the London School of Hygiene and Tropical Medicine The Gambia at the London School of Hygiene and Tropical Medicine Yamile Rodriguez Boston Children's Hospital Boston Children's Hospital Alec Plotkin Boston Children's Hospital Boston Children's Hospital Kerry McEnaney Boston Children's Hospital Boston Children's Hospital Bhav Dhillon University of British Columbia University of British Columbia Sebastiano Montante University of British Columbia University of British Columbia, BC Cancer Research Centre Rym Ben-Othman Telethon Kids Institute BC Cancer Research Centre, Telethon Kids Institute Tue Bennike Aalborg University Aalborg University, Boston Children’s Hospital, Harvard Medical School Benoit Fatou Boston Children's Hospital Boston Children's Hospital Casey Shannon University of British Columbia University of British Columbia Elena Morrocchi Bambino Gesù Childrens' Hospital Bambino Gesù Childrens' Hospital Travis Blimkie University of British Columbia University of British Columbia Abhinav Checkervarty University of British Columbia University of British Columbia
Publications:	None
Resources:
Assays:	Assay Type Number of Exp. Samples Luminex xMAP 152 Mass Spectrometry 357
Clinical Assessments:	None

---

SDY1760: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients with COVID-19
Status:	Updated
Description:	This is a prospective observational cohort of adult participants hospitalized with known or presumptive COVID-19.
Program/Contract:	Program Contract Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) Immunophenotyping for COVID-19 Cohort (IMPACC)
DOI:	10.21430/M3FCC2J1RF
Subjects:	1169
Study PI, contact:	Name Organization Site Bjoern Peters La Jolla Institute for Immunology La Jolla Institute for Immunology James A Overton Knocean, Inc Knocean, Inc Randi Vita La Jolla Institute for Immunology La Jolla Institute for Immunology Kerstin Westendorf La Jolla Institute for Immunology La Jolla Institute for Immunology
Publications:	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.. Science immunology Aug 2021. doi: 10.1126/sciimmunol.abf3733 [Pubmed: 34376480] Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.. EBioMedicine Aug 2022. doi: 10.1016/j.ebiom.2022.104208 [Pubmed: 35952496]
Resources:	ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04378777]
Assays:	None
Clinical Assessments:	None

---

SDY2537: Transcriptional signatures associated with induction of protective influenza stalk specific antibody and bone marrow plasma cells by mRNA vaccine in macaques
Status:	New
Description:	The authors utilized sequential immunization with mRNA vaccines expressing chimeric hemagglutinin (cHA) antigens to induce stalk specific humoral immunity in non-human primates (NHPs) with preexisting influenza virus immunity.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3ro5q6ubd
Subjects:	50
Study PI, contact:	Name Organization Site Rama Amara Emory University Emory University, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	None. None None None. doi: None [Pubmed: Not Applicable]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples ELISA 647 ELISPOT 345 Hemagglutination Inhibition 120
Clinical Assessments:	Physical Exam

---

SDY2584: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity - Papua New Guinea (PNG) Validation cohort
Status:	New
Description:	Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use. To gain insight into how vaccines induce protection of the most vulnerable, our project employs two novel approaches studying newborn responses to hepatitis B vaccine (HBV): (a) systems biology that uses technologies which comprehensively measure global changes in molecules such as transcriptomics (RNA) and proteomics (proteins), as well as cell composition of the blood and (b) use of human newborn blood components, collected prior to immunization, to model vaccine responses in vitro (outside the body). Characterizing vaccine-induced molecular patterns (signatures) that correspond to vaccine-mediated protection will accelerate development and optimization of vaccines against early life infections of major global health importance.
Program/Contract:	Program Contract Human Immunology Project Consortium (HIPC) RFA-AI-15-041 Systems Biology To Identify Biomarkers Of Neonatal Vaccine Immunogenicity (Boston Children's)
DOI:	10.21430/m3ec0qqknp
Subjects:	97
Study PI, contact:	Name Organization Site Ofer Levy Boston Children's Hospital Boston Children's Hospital, Harvard Medical School Tobias Kollmann University of British Columbia BC Children's Hospital, University of British Columbia Scott Tebbutt University of British Columbia PROOF Centre, University of British Columbia Robert Hancock University of British Columbia University of British Columbia Hanno Steen Boston Children's Hospital Boston Children's Hospital Ryan Brinkman University of British Columbia BC Cancer Agency, University of British Columbia Joann Arce Boston Children's Hospital Boston Children's Hospital, Harvard Medical School
Publications:	None
Resources:
Assays:	Assay Type Number of Exp. Samples DNA methylation profiling assay 35 Flow Cytometry 286 Luminex xMAP 197 Mass Spectrometry 264 Other 603 RNA sequencing 183
Clinical Assessments:	None

---

SDY2869: Maintenance of protective immunity to COVID-19 vaccines in multiple sclerosis patients on B cell-depleting therapy
Status:	New
Description:	Immune-mediated protection generated to COVID-19 mRNA vaccines is correlated to the presence of anti-Spike protein neutralizing antibodies. B cell depleting (BCD) therapies used to treat multiple sclerosis (MS), diminish this humoral response, though T cell-mediated immunity can be generated. To study the long-term persistence of these differential responses, the effects of different types and modes of immune modulators, and the resultant effects of protection in patients with MS, we evaluated the humoral and cellular response to COVID-19 vaccines in patients with MS from four centers, ranging from one to 70 weeks post-vaccination. BCD therapies in patients with MS significantly reduced the antibody response and enhanced the cellular response to COVID-19 vaccination, with some variations among different anti-CD20 drugs. Despite these alterations persisting for many months following vaccination, the patients retained protective immunity. These results highlight the critical role of T cell-mediated immunity in anti-viral protection independent of humoral immunity.
Program/Contract:	Program Contract Human Immunology Project Consortium (HIPC) RFA-AI-15-041 Human Anti-Viral Immune Responses In Tissues And Circulation (Columbia)
DOI:	10.21430/m3bl693zmo
Subjects:	109
Study PI, contact:	Name Organization Site Donna Farber Columbia University Columbia University Medical Center
Publications:	None
Resources:
Assays:	Assay Type Number of Exp. Samples Flow Cytometry 248
Clinical Assessments:	None

---

SDY3012: 18-color B-ALL MRD flow cytometry panel
Status:	New
Description:	18-color B-ALL MRD flow cytometry panel. Data include positive and negative cases.
Program/Contract:	Program Contract NIH Program Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning
DOI:	10.21430/M3CU7KC1WL
Subjects:	0
Study PI, contact:	Name Organization Site Paul Simonson Weill Cornell Medicine Weill Cornell Medicine
Publications:	None
Resources:
Assays:	None
Clinical Assessments:	None

---

SDY3083: Airway T cell Dynamics in Children with Treatment-Refractory Recurrent Wheeze
Status:	New
Description:	Severe asthma in children is notoriously difficult to treat, and its immunopathogenesis is complex. In particular, the contribution of T cells and relationships to antiviral immunity remain enigmatic. Here, we coupled deep phenotyping with machine learning methods to elucidate the dynamics of T cells in the lower airways of children with treatment-refractory recurrent wheeze, and examine rhinovirus (RV) as a driver. Our strategy revealed a T cell landscape dominated by type 1 and type 17 CD8+ signatures. Interrogation of phenotypic relationships coupled with trajectory mapping identified T cell migratory and differentiation pathways spanning the blood and airways that culminated in tissue residency, and involved transitions between type 1 and type 17 tissue-resident types. These dynamics were reflected in cytokine polyfunctionality. Use of machine learning tools to cross-compare T cell populations that were enriched in the airways of RV-positive children with those induced in the blood following experimental RV challenge precisely pinpointed RV-responsive signatures that contributed to T cell migratory and differentiation pathways. Despite their rarity, these signatures were also detected in the airways of RV-negative children. Together, our results underscore the aberrant nature of type 1 immunity in the airways of children with recurrent wheeze, and implicate an important viral trigger as a driver.
Program/Contract:	Program Contract NIH Program Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma
DOI:	10.21430/m3g54mxzb9
Subjects:	0
Study PI, contact:	Name Organization Site Judith Woodfolk University of Virginia Department of Medicine
Publications:	Rhinovirus as a driver of airway T cell dynamics in children with treatment-refractory recurrent wheeze.. JCI insight May 2025. doi: 10.1172/jci.insight.189480 [Pubmed: 40337866]
Resources:
Assays:	None
Clinical Assessments:	None

---

SDY3084: A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity
Status:	New
Description:	Brief description covers this.
Program/Contract:	Program Contract NIH Program IL-27 functions as a novel signal 3 cytokine and promotes cytotoxic T cell responses to tumors
DOI:	10.21430/m3d6pus0m7
Subjects:	0
Study PI, contact:	Name Organization Site Martin LaFleur Harvard Medical School NA Lauren Milling Harvard Medical School NA Arlene Sharpe Harvard Medical School NA
Publications:	None
Resources:
Assays:	None
Clinical Assessments:	None

---

SDY3088: Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice
Status:	New
Description:	The authors provide an in-depth characterization of the innate immune response and antigen-specific T-cellular immune response in mice.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3vqfcse7p
Subjects:	112
Study PI, contact:	Name Organization Site Kirill Vasilev Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC)
Publications:	None. None None None. doi: None [Pubmed: Not Applicable]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples Cytometric Bead Array Assay 80 Flow Cytometry 399 Virus Plaque Assay 96
Clinical Assessments:	None

---

SDY3093: Cytokine profiles in patients with chronic systolic heart failure
Status:	New
Description:	In this study we investigated chronic heart failure (HF)-associated cytokine signatures, both compared to healthy controls and in relation to chronic HF severity.
Program/Contract:	Program Contract NIH Program The Role of the Bifidobacterium Gut Microbiome Guild in Pathophysiology of Chronic Heart Failure with Reduced Ejection Fraction
DOI:	10.21430/m35z4vsb5n
Subjects:	0
Study PI, contact:	Name Organization Site Petra Mamic Stanford University Stanford Michael Snyder Stanford University Stanford
Publications:	None
Resources:	Link to BioRxiv pre-print https://www.biorxiv.org/content/10.1101/2024.08.06.606872v1.full.pdf]
Assays:	None
Clinical Assessments:	None

---

SDY3095: Purification and characterization of recombinant neuraminidase as a broadly protective influenza virus vaccine candidate
Status:	New
Description:	The authors detail the development of a downstream process for purifying of His-tagged recombinant neuraminidase for a phase I clinical study.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m38p03m9g9
Subjects:	0
Study PI, contact:	Name Organization Site Florian Krammer Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC)
Publications:	None. None None None. doi: None [Pubmed: Not Applicable]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3097: Analysis of SARS-CoV-2 infection and vaccination in high risk participants.
Status:	New
Description:	The study analyzed SARS-CoV-2 vaccination and infections in High Risk participants in the LA-SPARTA cohort. Samples were collected (blood and saliva) and serological responses to the SARS-CoV-2, RBD, and NP were assessed via ELISA assay. Notably, Hispanic participants are at a higher risk of breakthrough infection than non-Hispanic participants among vaccinated individuals.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/m39ybc30zv
Subjects:	200
Study PI, contact:	Name Organization Site Elaine Reed University of California at Los Angeles University of California at Los Angeles, CIVR-HRP
Publications:	Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants.. Frontiers in immunology Apr 2023. doi: 10.3389/fimmu.2023.1139915 [Pubmed: 37153624]
Resources:	Not Applicable https://pubmed.ncbi.nlm.nih.gov/37153624/]
Assays:	None
Clinical Assessments:	None

---

SDY3098: Induction of Antigen-Specific Tolerance in Multiple Sclerosis Model without Broad Immunosuppression
Status:	New
Description:	Microparticles made of acetalated dextran loaded with antigenic peptide and the tolerizing drug rapamycin (Rapa) were evaluated in an experimental autoimmune encephalomyelitis model induced by myelin oligodendrocyte glycoprotein (MOG) in both early and late therapeutic models to mimic different stages of Multiple Sclerosis.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/m3hlev7yxj
Subjects:	0
Study PI, contact:	Name Organization Site Kristy Ainslie University of North Carolina University of North Carolina, CIVR-HRP
Publications:	Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression.. ACS nano Jan 2025. doi: 10.1021/acsnano.4c14698 [Pubmed: 39812522]
Resources:	ACS link https://pubs.acs.org/doi/10.1021/acsnano.4c14698]
Assays:	None
Clinical Assessments:	None

---

SDY3099: Maturation of germinal center B cells after influenza virus vaccination in humans
Status:	New
Description:	The investigators used fine needle aspiration of draining lymph nodes to longitudinally track antigen-specific GC B cell responses to seasonal influenza vaccination.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m34jq7ijeq
Subjects:	1
Study PI, contact:	Name Organization Site Andrew Ward The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC) Ian Wilson The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC) Florian Krammer Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	Maturation of germinal center B cells after influenza virus vaccination in humans.. The Journal of experimental medicine Aug 2024. doi: 10.1084/jem.20240668 [Pubmed: 38935072]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples ELISA 48 Virus Neutralization 24
Clinical Assessments:	None

---

SDY3103: Assessing the structural boundaries of antibody interactions with Influenza hemagglutinin proteins
Status:	New
Description:	Investigation into how genetic drift in H3N2 viruses impacts broadly neutralizing antibodies by assessing the precise binding characteristics of three neutralizing monoclonal antibodies with H3 HA proteins. Antibody affinity and binding kinetics were analyzed by biolayer interferometry. The structural features of binding for each antibody with the COBRA HA NG2 protein were elucidated by cryo-EM.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/m3poauawjf
Subjects:	0
Study PI, contact:	Name Organization Site Jarrod Mousa Florida State University Florida State University, CIVR-HRP Rebecca DuBois University of California at Santa Cruz University of California at Santa Cruz, CIVR-HRP John Dzimianski University of California at Santa Cruz University of California at Santa Cruz, CIVR-HRP
Publications:	None. None None None. doi: None [Pubmed: Not Applicable]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3104: Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of VH3 and VK3 genes
Status:	New
Description:	Here, the authors structurally and biophysically characterize four antibodies that bind to a conserved region on the HA membrane-proximal region known as the anchor epitope.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3mkapvuoa
Subjects:	0
Study PI, contact:	Name Organization Site Ian Wilson The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC) Andrew Ward The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of V(H)3 and V(K)3 genes.. Nature communications Feb 2025. doi: 10.1038/s41467-025-56496-4 [Pubmed: 39894881]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3106: First Lung Infection Permanently Enlarges Lymph Nodes and Enhances New T Cell Responses
Status:	New
Description:	Here, the investigators perform immunology and vaccinology studies on naive specific pathogen-free mice responding to their very first respiratory challenge
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3b65z3nji
Subjects:	0
Study PI, contact:	Name Organization Site David Masopust University of Minnesota University of Minnesota, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	Cutting Edge: First Lung Infection Permanently Enlarges Lymph Nodes and Enhances New T Cell Responses.. Journal of immunology (Baltimore, Md. : 1950) Jun 2024. doi: 10.4049/jimmunol.2400010 [Pubmed: 38619284]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3109: Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens
Status:	New
Description:	Using X-ray crystallography and negative-stain electron microscopy, the authors determined structures of cH5/1, cH8/1, and cH11/1 HAs in their unliganded and antibody Fab-bound states.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3b3zt7u85
Subjects:	0
Study PI, contact:	Name Organization Site Ian Wilson The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC) Florian Krammer Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC) Peter Palese Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC) Andrew Ward The Scripps Research Institute The Scripps Research Institute, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC)
Publications:	Structural characterization of influenza group 1 chimeric hemagglutinins as broad vaccine immunogens.. Proceedings of the National Academy of Sciences of the United States of America Feb 2025. doi: 10.1073/pnas.2416628122 [Pubmed: 39937865]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3110: Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Status:	New
Description:	The authors investigate whether neutralization is markedly impaired, against Omicron and its subvariants, for individuals vaccinated/boosted with SARS-CoV-2 vaccines or those previously infected.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/m3ctv4518x
Subjects:	0
Study PI, contact:	Name Organization Site Aubree Gordon University of Michigan University of Michigan, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.. Cell Jan 2023. doi: 10.1016/j.cell.2022.12.018 [Pubmed: 36580913]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3118: Immunophenotyping by Spectral Flow Cytometry of 12-month Sjögren's IL14alpha and WT Murine SMG
Status:	New
Description:	Immunophenotyping data using spectral flow cytometry to characterize the B and T cell populations present in the submandibular glands from IL-14alpha transgenic Sjögren's mice and C57BL/6 wildtype (WT) female mice at 12 months of age.
Program/Contract:	Program Contract NIH Program lluminating the Role of the Novel G Protein-Coupled P2Y10 Receptor in Sjögren’s Disease Pathophysiology
DOI:	10.21430/m3bxs9gyqu
Subjects:	11
Study PI, contact:	Name Organization Site Lucas Woods University of Missouri University of Missouri Kimberly Jasmer University of Louisville University of Missouri Kevin Muñoz Forti University of Chicago University of Missouri Gary Weisman University of Missouri University of Missouri
Publications:	None
Resources:
Assays:	Assay Type Number of Exp. Samples Flow Cytometry 38
Clinical Assessments:	None

---

SDY3119: Multivalent COBRA influenza vaccine elicits immune response in pre-immune ferrets
Status:	New
Description:	Investigation of the immune response and effectiveness of the next-generation hemagglutinin and neuraminidase proteins, designed using computationally optimized broadly reactive antigen (COBRA) methodology, in elderly ferrets. The animals were pre-immunized with Sing/86 and Pan/99 and prime-boost vaccinated with mixtures of COBRA-based influenza vaccines (J4, Y2, NG2, NG7, NG8, N1-I, and N2-B), and Infectimune adjuvant. The elderly ferrets were challenged with Tas/20; blood samples and nasal washes were collected for several analyses.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/m3bra9cso9
Subjects:	36
Study PI, contact:	Name Organization Site Ted Ross Other: Cleveland Clinic University of Georgia, Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
Publications:	Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.. Vaccine May 2025. doi: 10.1016/j.vaccine.2025.127156 [Pubmed: 40267617]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	Physical Exam

Updated Studies

SDY1538: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Status:	Updated
Description:	Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use. To gain insight into how vaccines induce protection of the most vulnerable, our project employs two novel approaches studying newborn responses to hepatitis B vaccine (HBV): (a) systems biology that uses technologies which comprehensively measure global changes in molecules such as transcriptomics (RNA) and proteomics (proteins), as well as cell composition of the blood and (b) use of human newborn blood components, collected prior to immunization, to model vaccine responses in vitro (outside the body). Characterizing vaccine-induced molecular patterns (signatures) that correspond to vaccine-mediated protection will accelerate development and optimization of vaccines against early life infections of major global health importance.
Program/Contract:	Program Contract Human Immunology Project Consortium (HIPC) RFA-AI-15-041 Systems Biology To Identify Biomarkers Of Neonatal Vaccine Immunogenicity (Boston Children's)
DOI:	10.21430/M35PWV2M56
Subjects:	720
Study PI, contact:	Name Organization Site Ofer Levy Boston Children's Hospital Boston Children's Hospital, Harvard Medical School Tobias Kollmann University of British Columbia BC Children's Hospital, University of British Columbia Beate Kampmann Medical Research Council- The Gambia, Medical Research Council- The Gambia, Al Ozonoff Boston Children's Hospital Boston Children's Hospital Scott Tebbutt University of British Columbia PROOF Centre, University of British Columbia Robert Hancock University of British Columbia University of British Columbia Hanno Steen Boston Children's Hospital Boston Children's Hospital Ryan Brinkman University of British Columbia BC Cancer Agency, University of British Columbia
Publications:	Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea.. Frontiers in pediatrics Apr 2020. doi: 10.3389/fped.2020.00197 [Pubmed: 32426309]
Resources:	ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03246230]
Assays:	Assay Type Number of Exp. Samples DNA methylation profiling assay 1334 Flow Cytometry 6645 Luminex xMAP 1353 Mass Spectrometry 1364 Other 10037 RNA sequencing 1339
Clinical Assessments:	None

---

SDY1644: Urban Environmental Factors and Childhood Asthma (URECA) (ICAC-07)
Status:	Updated
Description:	The purpose of this study is to determine the way environmental factors (like the components of inner-city household dust) affect immune system development and symptoms of asthma in inner city children. The study is divided into three periods, as the subjects age from birth to 10 years old. Each age bracket will explore different objectives and endpoints. Study Objectives/Hypotheses: Subjects age 0 to 3 years old: Environmental factors in the inner city adversely influence the development of the immune system to promote cytokine dysregulation, allergy, and recurrent wheezing by age 3. Children who have had a viral lower respiratory infection and have developed cytokine dysregulation by age 3 are at increased risk for the development of asthma by age 6. Subjects age 4 to 7 years old: There is a unique pattern of immune development that is driven by specific urban exposures in early life, and this pattern of immune development is characterized by: 1) impairment of antiviral responses and 2) accentuation of Th2-like responses (e.g. cockroach-specific Interleukin-13(IL-13)). The clinical effects of these changes in immune development are frequent virus-induced wheezing and allergic sensitization by 3-4 years of age, and these characteristics synergistically increase the risk of asthma at age 7 years. Subjects age 7 to 10 years old: There are unique combinations of environmental exposures (cockroach allergens, indoor pollutants [Environmental Tobacco Smoke (ETS) and Nitrogen Dioxide (NO2)], lack of microbial exposure), and family characteristics (stress, genetic factors related to innate immunity) that synergistically promote asthma onset, persistence, and morbidity in urban neighborhoods. These exposures and characteristics influence immune expression and lung development during critical periods of growth, resulting in specific asthma phenotypes. Subjects age 10 to 16 years old: To determine the wheezing, asthma and atopy phenotypes in minority children growing up in poor urban neighborhoods as they develop from birth through adolescence.
Program/Contract:	Program Contract Inner City Asthma Consortium (ICAC) RFA-AI-13-036 INNER CITY ASTHMA CONSORTIUM 3 (ICAC3)
DOI:	10.21430/M3H1YHLR5Z
Subjects:	1218
Study PI, contact:	Name Organization Site James Gern University of Wisconsin School of Medicine and Public Health University of Wisconsin School of Medicine and Public Health
Publications:	Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study.. BMC immunology Dec 2006. doi: 10.1186/1471-2172-7-29 [Pubmed: 17156490] The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population.. BMC pulmonary medicine May 2009. doi: 10.1186/1471-2466-9-17 [Pubmed: 19426496] Characterization of regulatory T cells in urban newborns.. Clinical and molecular allergy : CMA Jul 2009. doi: 10.1186/1476-7961-7-8 [Pubmed: 19586545] Parental characteristics, somatic fetal growth, and season of birth influence innate and adaptive cord blood cytokine responses.. The Journal of allergy and clinical immunology Nov 2009. doi: 10.1016/j.jaci.2009.08.021 [Pubmed: 19895995] Prenatal maternal stress and cord blood innate and adaptive cytokine responses in an inner-city cohort.. American journal of respiratory and critical care medicine Jul 2010. doi: 10.1164/rccm.200904-0637OC [Pubmed: 20194818] Retention strategies and predictors of attrition in an urban pediatric asthma study.. Clinical trials (London, England) Aug 2010. doi: 10.1177/1740774510373798 [Pubmed: 20571137] Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study).. The Journal of allergy and clinical immunology Apr 2011. doi: 10.1016/j.jaci.2010.12.1122 [Pubmed: 21333343] Umbilical cord plasma 25-hydroxyvitamin D concentration and immune function at birth: the Urban Environment and Childhood Asthma study.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Jun 2011. doi: 10.1111/j.1365-2222.2011.03712.x [Pubmed: 21481021] Longitudinal relationship of early life immunomodulatory T cell phenotype and function to development of allergic sensitization in an urban cohort.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Mar 2012. doi: 10.1111/j.1365-2222.2011.03882.x [Pubmed: 22092655] Antiviral IFN-g responses of monocytes at birth predict respiratory tract illness in the first year of life.. The Journal of allergy and clinical immunology May 2012. doi: 10.1016/j.jaci.2012.02.033 [Pubmed: 22460071] Comparison of the etiology of viral respiratory illnesses in inner-city and suburban infants.. The Journal of infectious diseases Nov 2012. doi: 10.1093/infdis/jis504 [Pubmed: 23014674] Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children.. The Journal of allergy and clinical immunology Sep 2014. doi: 10.1016/j.jaci.2014.04.018 [Pubmed: 24908147] Influence of early-life exposures on food sensitization and food allergy in an inner-city birth cohort.. The Journal of allergy and clinical immunology Jan 2015. doi: 10.1016/j.jaci.2014.06.033 [Pubmed: 25129677] Relation between stress and cytokine responses in inner-city mothers.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Nov 2015. doi: 10.1016/j.anai.2015.07.021 [Pubmed: 26409873] The influence of atopy and asthma on immune responses in inner-city adults.. Immunity, inflammation and disease Mar 2016. doi: 10.1002/iid3.96 [Pubmed: 27042305] Relationships among Maternal Stress and Depression, Type 2 Responses, and Recurrent Wheezing at Age 3 Years in Low-Income Urban Families.. American journal of respiratory and critical care medicine Mar 2017. doi: 10.1164/rccm.201602-0272OC [Pubmed: 27654103] Asthma phenotypes in inner-city children.. The Journal of allergy and clinical immunology Oct 2016. doi: 10.1016/j.jaci.2016.06.061 [Pubmed: 27720016] Patterns of immune development in urban preschoolers with recurrent wheeze and/or atopy.. The Journal of allergy and clinical immunology Sep 2017. doi: 10.1016/j.jaci.2016.10.052 [Pubmed: 28089873] Early-life home environment and risk of asthma among inner-city children.. The Journal of allergy and clinical immunology Apr 2018. doi: 10.1016/j.jaci.2017.06.040 [Pubmed: 28939248] Development of Asthma in Inner-City Children: Possible Roles of MAIT Cells and Variation in the Home Environment.. Journal of immunology (Baltimore, Md. : 1950) Mar 2018. doi: 10.4049/jimmunol.1701525 [Pubmed: 29431692] Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy.. The journal of allergy and clinical immunology. In practice Sep 2018. doi: 10.1016/j.jaip.2017.12.028 [Pubmed: 29449165] Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma.. The Journal of allergy and clinical immunology Dec 2018. doi: 10.1016/j.jaci.2018.02.019 [Pubmed: 29518416] Longitudinal Phenotypes of Respiratory Health in a High-Risk Urban Birth Cohort.. American journal of respiratory and critical care medicine Jan 2019. doi: 10.1164/rccm.201801-0190OC [Pubmed: 30079758] Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-dependent blood DNA methylation levels.. Epigenetics Jun 2021. doi: 10.1080/15592294.2020.1817290 [Pubmed: 32997571] Endotype of allergic asthma with airway obstruction in urban children.. The Journal of allergy and clinical immunology Nov 2021. doi: 10.1016/j.jaci.2021.02.040 [Pubmed: 33713771] Fine-mapping studies distinguish genetic risks for childhood- and adult-onset asthma in the HLA region.. Genome medicine May 2022. doi: 10.1186/s13073-022-01058-2 [Pubmed: 35606880] Multi-omic association study identifies DNA methylation-mediated genotype and smoking exposure effects on lung function in children living in urban settings.. PLoS genetics Jan 2023. doi: 10.1371/journal.pgen.1010594 [Pubmed: 36638096]
Resources:	ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00114881] SRA SRP102104 https://trace.ncbi.nlm.nih.gov/Traces/?view=study&acc=SRP102104] GEO GSE96783 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96783] BioProject https://www.ncbi.nlm.nih.gov/bioproject/PRJNA379624] SRA SRP249918 https://trace.ncbi.nlm.nih.gov/Traces/?view=study&acc=SRP249918] GEO GSE145505 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145505] BioProject https://www.ncbi.nlm.nih.gov/bioproject/PRJNA607333] dbGaP https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002921.v2.p1] GEO GSE132181 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132181] BioProject https://www.ncbi.nlm.nih.gov/bioproject/PRJNA546267] Related study - SDY1025 https://www.immport.org/shared/search?text=sdy1025]
Assays:	Assay Type Number of Exp. Samples DNA methylation profiling assay 392 RNA sequencing 866
Clinical Assessments:	asthma primary definition Baby Birth Record Child Bedroom Environment Daycare Environment Heating and Appliances in Home Home dust allergen levels and assays Home Environmental Issues Home Smoking Environment Maternal Alcohol Use History Maternal Smoking History Medical Record During Labor and Delivery Medical Record During Pregnancy Other Residence Environment Overall Animal Exposure Spirometry Spirometry Reversibility

---

SDY2903: High-throughput single-cell profiling of B cell responses following inactivated influenza vaccination in young and older adults
Status:	Updated
Description:	Seasonal influenza contributes to a substantial disease burden, resulting in approximately 10 million hospital visits and 50 thousand deaths in a typical year in the United States. 70 - 85% of the mortality occurs in people over the age of 65. Influenza vaccination is the best protection against the virus, but it is less effective for the elderly, which may be in part due to differences in the quantity or type of B cells induced by vaccination. To investigate this possibility, we sorted pre- and post-vaccination peripheral blood B cells from three young and three older adults with strong antibody responses to the inactivated influenza vaccine and employed single-cell technology to simultaneously profile the gene expression and the B cell receptor (BCR) of the B cells. Prior to vaccination, we observed a higher somatic hypermutation frequency and a higher abundance of activated B cells in older adults than in young adults. Following vaccination, young adults mounted a more clonal response than older adults. The expanded clones included a mix of plasmablasts, activated B cells, and resting memory B cells in both age groups, with a decreased proportion of plasmablasts in older adults. Differential abundance analysis identified additional vaccine-responsive cells that were not part of expanded clones, especially in older adults.
Program/Contract:	Program Contract Human Immunology Project Consortium (HIPC) RFA-AI-15-041 Systems Immune Profiling Of Divergent Responses To Infection (Yale)
DOI:	10.21430/M3GUD62MN9
Subjects:	6
Study PI, contact:	Name Organization Site Steven Kleinstein Yale University NA
Publications:	High-throughput single-cell profiling of B cell responses following inactivated influenza vaccination in young and older adults.. Aging Jun 2023. doi: 10.18632/aging.204778 [Pubmed: 37367734]
Resources:	GSE175524 https://bitbucket.org/kleinstein/projects/src/master/Wang2023_Aging]
Assays:	Assay Type Number of Exp. Samples B cell receptor repertoire sequencing assay 12 RNA sequencing 12
Clinical Assessments:	None

---

SDY2918: A surrogate ELISA to select high titer human convalescent plasma for treating immunocompromised patients infected with SARS-CoV-2 variants of concern
Status:	Updated
Description:	Here, the authors review a surrogate ELISA to select COVID-19 convalescent plasma samples that will guarantee a protective level of neutralizing antibodies as the main correlate of protection.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/M36AY0IIO6
Subjects:	625
Study PI, contact:	Name Organization Site Peter Palese Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC) Florian Krammer Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC) Viviana Simon Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC)
Publications:	None. None None None. doi: None [Pubmed: Not Applicable]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples ELISA 1088 Virus Neutralization 332 Virus Plaque Assay 19
Clinical Assessments:	Infection Not Applicable Second-infection

---

SDY2963: A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Status:	Updated
Description:	Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)-lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Duke CIVIC Vaccine Center (DCVC)
DOI:	10.21430/M3ZUEULG98
Subjects:	172
Study PI, contact:	Name Organization Site Scott Hensley University of Pennsylvania University of Pennsylvania, Duke CIVICs Vaccine Center (DCVC)
Publications:	A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes.. Science (New York, N.Y.) Nov 2022. doi: 10.1126/science.abm0271 [Pubmed: 36423275]
Resources:	Science https://doi.org/10.1126/science.abm0271]
Assays:	Assay Type Number of Exp. Samples ELISA 139
Clinical Assessments:	Not Applicable

---

SDY3015: Flu-COVID combination vaccine and immune response
Status:	Updated
Description:	Healthy mice were vaccinated with a combination flu-COVID vaccine, COBRA H1 and H3, and antibody response was analyzed after being challenged with virus. The combination vaccine is being tested to administer one seasonal vaccine as opposed to two.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/M35PZ7ECKM
Subjects:	130
Study PI, contact:	Name Organization Site Ted Ross Other: Cleveland Clinic University of Georgia, Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
Publications:	Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.. Vaccine Feb 2024. doi: 10.1016/j.vaccine.2023.12.084 [Pubmed: 38296701]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples ELISA 1035 Hemagglutination Inhibition 2100 Virus Neutralization 95 Virus Plaque Assay 30
Clinical Assessments:	Not Applicable

---

SDY3060: Enhancing NA immunogenicity through novel VLP designs.
Status:	Updated
Description:	Here, the investigators aimed at enhancing the immunogenicity of the NA on vaccines by two strategies: (i) modifying the HA:NA ratio of the vaccine preparation and (ii) exposing epitopes on the lateral surface or beneath the head of the NA by extending the NA stalk.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/M3TVD7CEA3
Subjects:	60
Study PI, contact:	Name Organization Site Florian Krammer Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai, Sinai-Emory Multi-Institutional CIVIC (SEM-CIVIC)
Publications:	Enhancing NA immunogenicity through novel VLP designs.. Vaccine Oct 2024. doi: 10.1016/j.vaccine.2024.126270 [Pubmed: 39197219]
Resources:	Not Applicable Not Applicable]
Assays:	Assay Type Number of Exp. Samples ELISA 240 Hemagglutination Inhibition 120 Other 120
Clinical Assessments:	Not Applicable

---

SDY3077: Mutability and hypermutation antagonize immunoglobulin codon optimality
Status:	Updated
Description:	The authors analyze germline immunoglobulin genes, natural V(D)J repertoires, serum IgG and monoclonal antibody (mAb) expression through the lens of codon optimality.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
DOI:	10.21430/M32KYWVYGO
Subjects:	0
Study PI, contact:	Name Organization Site Patrick Wilson Cornell University Cornell University, Sinai-Emory Multi-Institutional CIVIC (SEM CIVIC)
Publications:	Mutability and hypermutation antagonize immunoglobulin codon optimality.. Molecular cell Jan 2025. doi: 10.1016/j.molcel.2024.11.033 [Pubmed: 39708804]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	None

---

SDY3079: COBRA N2 NA/NB vaccines and immune response
Status:	Updated
Description:	A recombinant COBRA N2 NA vaccine was used to elicit immune response in mice following an influenza challenge of SW/NC/15 and Kan/17. Hemagglutination-Inhibition (HAI) and influenza viral plaque assays were conducted using the mice sera samples to detect an increased antibody response that would prove more effective than current seasonal vaccines.
Program/Contract:	Program Contract CIVICs Collaborative Influenza Vaccine Innovation Centers Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
DOI:	10.21430/M3BXRFFJK0
Subjects:	213
Study PI, contact:	Name Organization Site Ted Ross Other: Cleveland Clinic University of Georgia, Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)
Publications:	COBRA N2 NA vaccines induce protective immune responses against influenza viral infection.. Human vaccines & immunotherapeutics Dec 2024. doi: 10.1080/21645515.2024.2403175 [Pubmed: 39291424]
Resources:	Not Applicable Not Applicable]
Assays:	None
Clinical Assessments:	Not Applicable